Treatable Bilateral Striatal Lesions Related to Anti-Dopamine 2 Receptor
Neurol 91:98-101, Marques-Matos, C.,et al, 2018
Complementary Positron Emission Tomographic Studies of the Striatal Dopaminergic System in Parkinson's Disease
Arch Neurol 52:1183-1190, Antonini,A.,et al, 1995
Treatment with D-penicillamine Improves Dopamine D2-Receptor Binding and T2-Signal Intensity in de novo Wilson's Disease
Neurol 44:1079-1082, Schwarz,J.,et al, 1994
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993
Schizophrenia as a Brain Disease, The Dopamine Receptor Story
Arch Neurol 50:1093-1095, 10971993., Seeman,P., 1993
Striatal D2 Receptor Status in Patients with Parkinson's Disease, Striatonigral Degeneration, and PSP, (PET)
Ann Neurol 31:184-192, Brooks,D.J.,et al, 1992
123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism
Neurol 42:556-561, Schwarz,J.,et al, 1992
Dopamine Agonist Treatment of Fluctuating Parkinsonisn
Arch Neurol 49:560-568, Ahlskog,J.E.,et al, 1992
Physiology & Pharmacology of Dopamine D2-Receptors:Their Implications in Dopamine-Substitute Therapy for Park
Neurol 39:1106-1108, Mercuri,N.B.,et al, 1989
Dopamine D2 Receptor Density Remains Constant in Treated Parkinson's Disease
Ann Neurol 19:487-492, Guttman,M.,et al, 1986